DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Treatment-Resistant Depression (TRD) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of TRD, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Treatment-Resistant Depression (TRD) Market
The total market size of TRD in the 7MM was approximately USD 3,726 million in 2022 and is projected to reach nearly USD 5,874 million by 2036.
As per DelveInsight analysis, there were approximately 6.6 million prevalent cases of TRD across the 7MM in 2025, and this figure is projected to rise by 2036.
The United States accounted for nearly 71% of the patient share of TRD cases in the 7MM in 2025.
In 2025, an estimated 1.2 million males and 3.4 million females in the US were affected by TRD, indicating higher prevalence among females.
Germany reported the highest number of TRD cases among the EU4 and the UK in 2025, with approximately 600,000 prevalent cases.
Italy had the lowest prevalent population of TRD in 2025, with approximately 140 thousand cases.
The TRD treatment pipeline includes emerging therapies such as COMP360 by COMPASS Pathways, BPL-003 by Atai Beckley, and VLS-01 by Atai Beckley.
In January 2025, Johnson & Johnson announced that SPRAVATO (esketamine) received approval in the US as the first and only monotherapy specifically indicated for adults with TRD.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving the Treatment-Resistant Depression Market
Increasing Burden of Depression and Treatment Resistance:A growing number of patients fail to respond adequately to conventional antidepressants despite appropriate treatment duration and dosage, significantly increasing the burden of TRD globally.
Advancements in Psychedelic-Based Therapies:The emergence of novel psychedelic-based therapies such as psilocybin and DMT-derived treatments is expected to transform the TRD treatment landscape by offering rapid and durable antidepressant effects.
Growing Adoption of Innovative Therapies:The increasing acceptance and clinical adoption of therapies such as SPRAVATO, transcranial magnetic stimulation (TMS), and other neuromodulation approaches are improving treatment outcomes in TRD patients.
Rising Awareness Regarding Mental Health Disorders:Improved awareness campaigns, expanded mental healthcare access, and growing recognition of depression-related disabilities are contributing to earlier diagnosis and better treatment access.
Treatment-Resistant Depression Competitive Landscape
Several companies are actively working to strengthen the TRD pipeline through innovative treatment approaches. Key companies involved in the TRD market include COMPASS Pathways, Atai Beckley, Johnson & Johnson, and others.
Promising therapies such as COMP360, BPL-003, and VLS-01 are currently being evaluated in clinical studies for their potential to deliver rapid antidepressant responses with durable efficacy.
Discover more about therapies set to grab major Treatment-Resistant Depression market share @ Treatment-Resistant Depression Treatment Landscape
Recent Developments in the Treatment-Resistant Depression Market
In May 2026, COMPASS Pathways announced that the Phase III COMP006 trial of COMP360 psilocybin in TRD met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in MADRS scores at Week 6.
In March 2026, Atai Beckley reported key clinical and regulatory updates for BPL-003 and announced plans to initiate Phase III development in Q2 2026 following a successful End-of-Phase II meeting with the FDA.
In November 2025, Atai Beckley reported positive Phase IIb open-label extension data for BPL-003, with the 12 mg dose showing sustained antidepressant effects for up to two months.
In January 2026, Johnson & Johnson presented new post-hoc Phase III analyses evaluating the effects of SPRAVATO on anhedonia in adults with TRD at the American College of Neuropsychopharmacology Annual Meeting.
In November 2025, Atai Beckley announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech focused on psychedelic-based neuroplastogens for mental health disorders.
What is Treatment-Resistant Depression (TRD)?
Treatment-Resistant Depression generally refers to a condition in which individuals do not respond adequately to at least one course of antidepressant therapy administered at appropriate doses and duration.
TRD is influenced by biological, psychological, and environmental factors including genetic predisposition, neurotransmitter imbalances, chronic stress, trauma, socioeconomic challenges, family conflicts, and comorbid conditions.
Current treatment approaches for TRD include pharmacological strategies such as switching or augmenting antidepressants, along with non-pharmacological treatments including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and cognitive behavioral therapy (CBT).
Treatment-Resistant Depression Epidemiology Segmentation
The Treatment-Resistant Depression epidemiology section provides insights into the historical and current TRD patient pool and forecasted trends for the leading markets. The TRD market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Prevalent Cases of TRD
Gender-specific Prevalent Cases of TRD
Age-specific Prevalent Cases of TRD
Diagnosed Prevalent Cases of MDD
Treatment Eligible Population
Treated Cases of MDD
Scope of the Treatment-Resistant Depression Market Report
Therapeutic Assessment: TRD current marketed and emerging therapies
TRD Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: COMPASS Pathways, Atai Beckley, Johnson & Johnson, and others
Key Therapies: SPRAVATO, COMP360, BPL-003, VLS-01, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, TRD Market Access and Reimbursement
To know more about Treatment-Resistant Depression companies working in the treatment market, visit @ Treatment-Resistant Depression Clinical Trials and Therapeutic Assessment
Table of Contents
Treatment-Resistant Depression Market Report Introduction
Executive Summary for TRD
SWOT Analysis of TRD
TRD Patient Share (%) Overview at a Glance
TRD Market Overview at a Glance
TRD Disease Background and Overview
TRD Epidemiology and Patient Population
Country-Specific Patient Population of TRD
TRD Current Treatment and Medical Practices
TRD Unmet Needs
TRD Emerging Therapies
TRD Market Outlook
Country-Wise TRD Market Analysis (2022–2036)
TRD Market Access and Reimbursement of Therapies
TRD Market Drivers
TRD Market Barriers
TRD Appendix
TRD Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: https://www.delveinsight.com/consulting/due-diligence-servicesCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
